Replies to post #141884 on Cytodyn Inc (CYDY)

[Dieselpro]

HIV...now that Leronlimab is proven for HIV revenue will be in the billions. That's $40 share price alone. Combine that with covid-19 and longhaulers it's approaching $100. And the best part is now that Leronlimab met it's primary endpoints in the HIV trial it really de-risks the covid-19 investment. It's an excellent time to be a CYDY shareholder.

[pablok]

So far just one for Phase 3 HIV Combo Therapy:

CytoDyn has successfully completed a Phase 3 pivotal trial with Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients meeting its primary endpoint. 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with viral load suppression of < 50 cp/mL.

That being said there are countless other small biotechs that have yet to have a Phase 3 Trial meet a PE.

[moneycrew]

Do you have any proof they did not reach endpoints?